<DOC>
	<DOCNO>NCT02829775</DOCNO>
	<brief_summary>This open label extension study give opportunity participant respond treatment Pegylated-Interferon Alfa-2a ( Pegasys ) Recombinant Interferon Alfa-2a ( Roferon-A® ) prior clinical study NO15753 ( NCT00003542 ) Renal Cell Carcinoma ( RCC ) , NO15764 ( NCT number available ) NO16006 ( NCT02736721 ) Chronic Myelogenous Leukemia ( CML ) , NO16007 ( NCT number available ) Malignant Melanoma ( MM ) .</brief_summary>
	<brief_title>A Study Continued Treatment Among Participants Who Have Responded Peginterferon Alfa-2a ( Pegasys® ) Recombinant Interferon Alfa-2a ( Roferon-A® ) Prior Clinical Studies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Participants must complete protocol NO15753 , NO15764 , NO16006 NO16007 respond treatment end trial define parent protocol CML participant must confirm cytogenetic complete response within 2 month enter extension study . MM RCC participant must tumour assessment verify stable good response within 2 month enter extension study Pregnant lactate woman Refusal use adequate contraceptive measure among men woman childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>